Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06214052 · ClinicalTrials.gov registry record · Phase 2
VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
A Phase 2 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT06214052 is a Phase 2 study that has completed, run by ViiV Healthcare. The registered enrollment target is 22 participants.
The verdict
NCT06214052, a Phase 2 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future.
Interventions
- DRUG Matching Placebo
- DRUG VH4524184
- DRUG Antiretroviral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2024-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06214052
The ClinicalTrials.gov registry entry for NCT06214052 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Matching Placebo is the first listed.
NCT06214052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06214052 about?
NCT06214052 is a clinical study titled "VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1". The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184...
What is the current status of trial NCT06214052?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2024-02-07. Estimated completion is 2024-06-12.
What interventions are being tested in trial NCT06214052?
The interventions under investigation include: Matching Placebo (DRUG), VH4524184 (DRUG), Antiretroviral therapy (DRUG).
Who is sponsoring clinical trial NCT06214052?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.